UBS reiterates buy rating on Moderna stock, maintains $70 price target

Investing.comTuesday, September 16, 2025 at 2:37:36 PM
UBS reiterates buy rating on Moderna stock, maintains $70 price target
UBS has reaffirmed its buy rating on Moderna's stock and maintained a price target of $70. This endorsement reflects confidence in Moderna's future performance.
Editor’s Note: This matters because a strong buy rating from a major financial institution like UBS can influence investor sentiment and potentially drive the stock price higher, benefiting shareholders.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Inditex stock rating upgraded to Buy by UBS on strong growth
PositiveFinancial Markets
UBS has upgraded Inditex's stock rating to 'Buy' due to strong growth prospects. This positive outlook reflects confidence in the company's performance and market position.
Editor’s Note: This upgrade is significant as it indicates investor confidence in Inditex's future, potentially leading to increased stock value and attracting more investors. It highlights the company's resilience and growth potential in a competitive retail market.
Phillips 66 stock: UBS reiterates Buy rating on refining expansion
PositiveFinancial Markets
UBS has reaffirmed its Buy rating on Phillips 66, highlighting the company's ongoing refining expansion efforts. This positive outlook reflects confidence in the company's growth potential in the refining sector.
Editor’s Note: This matters because a Buy rating from a major financial institution like UBS can influence investor confidence and stock performance. Phillips 66's expansion in refining could lead to increased profitability, making it an attractive investment.
UBS reiterates Neutral rating on Norwegian Cruise Line stock at $27
NeutralFinancial Markets
UBS has maintained a Neutral rating on Norwegian Cruise Line's stock, setting a price target of $27. This indicates a stable outlook for the company amidst market fluctuations.
Editor’s Note: This matters because stock ratings can influence investor decisions. A Neutral rating suggests that UBS does not foresee significant changes in the stock's performance, which can help investors gauge their strategies.
UBS maintains Crocs stock rating at Neutral amid North America growth concerns
NeutralFinancial Markets
UBS has kept its stock rating for Crocs at Neutral due to concerns about growth in North America. This decision reflects the cautious outlook on the company's performance in that region.
Editor’s Note: This matters because stock ratings can significantly influence investor decisions. By maintaining a Neutral rating, UBS indicates that while Crocs has potential, there are uncertainties that investors should consider, particularly in the North American market.
Kimco stock maintains Buy rating at UBS on redevelopment potential
PositiveFinancial Markets
UBS has maintained a Buy rating for Kimco stock, highlighting its strong potential for redevelopment. This positive outlook reflects confidence in the company's future growth and investment opportunities.
Editor’s Note: This matters because a Buy rating from a reputable firm like UBS can influence investor confidence and stock performance. It suggests that Kimco is well-positioned for future success, which could attract more investors and drive up stock prices.
UBS reiterates Neutral rating on Federal Realty stock after Assembly Row tour
NeutralFinancial Markets
UBS has maintained a neutral rating on Federal Realty's stock following a recent tour of Assembly Row. This indicates a cautious outlook on the company's performance.
Editor’s Note: This matters because UBS's rating can influence investor decisions and market perceptions of Federal Realty, especially after their firsthand assessment of the Assembly Row development.
ResMed stock maintains Buy rating at UBS amid GLP-1 impact assessment
PositiveFinancial Markets
ResMed's stock continues to hold a Buy rating from UBS as the firm assesses the impact of GLP-1 medications on the market. This positive outlook reflects confidence in ResMed's performance amid changing healthcare dynamics.
Editor’s Note: This matters because maintaining a Buy rating indicates strong investor confidence in ResMed's future, especially as the healthcare landscape evolves with new treatments like GLP-1. Investors often look to analysts' ratings to guide their decisions.
Royalty Pharma stock price target raised to $38 from $37 at UBS
PositiveFinancial Markets
UBS has raised its price target for Royalty Pharma's stock from $37 to $38, indicating a positive outlook for the company.
Editor’s Note: This adjustment in the price target reflects UBS's confidence in Royalty Pharma's performance, which could influence investor sentiment and market dynamics.
California Resources stock price target raised to $70 from $63 at UBS
PositiveFinancial Markets
UBS has raised its stock price target for California Resources from $63 to $70, indicating a positive outlook for the company.
Editor’s Note: This adjustment reflects UBS's confidence in California Resources' performance and potential growth, which could attract more investors and positively impact the stock market.
Chord Energy stock price target raised to $130 by UBS on Williston acquisition
PositiveFinancial Markets
UBS has raised the stock price target for Chord Energy to $130 following its acquisition of Williston. This move reflects confidence in Chord's growth potential.
Editor’s Note: This is significant as it indicates strong market confidence in Chord Energy's strategic decisions and future profitability, which could attract more investors.
Swedish central bank’s next rate decision is a "close call," UBS says. Here’s why.
NeutralFinancial Markets
UBS analysts describe the upcoming rate decision by the Swedish central bank as a 'close call,' indicating uncertainty in the economic outlook.
Editor’s Note: This matters because the central bank's decision will impact interest rates, inflation, and overall economic stability in Sweden, influencing both consumers and businesses.
UBS says U.K. equities aren’t just value plays anymore
PositiveFinancial Markets
UBS has highlighted that U.K. equities are evolving beyond mere value investments, indicating a shift in market dynamics.
Editor’s Note: This matters because it suggests that investors may find new opportunities in U.K. equities, potentially leading to increased market interest and investment strategies.
Latest from Financial Markets
Beijing says TikTok’s US app will use Chinese algorithm
NeutralFinancial Markets
Beijing announced that TikTok's US app will utilize a Chinese algorithm. This comes as Donald Trump extends the deadline for a potential shutdown of the platform, indicating ongoing negotiations with China.
Editor’s Note: This development is significant as it highlights the complexities of international relations and technology. The use of a Chinese algorithm in a US app raises concerns about data privacy and security, while the extended deadline suggests that a resolution may be on the horizon.
BofA sees gold hitting $4,000 per ounce in the second quarter of 2026. Here’s why the bank sees more room to run after recent record highs
PositiveFinancial Markets
Bank of America predicts that gold prices could reach $4,000 per ounce by the second quarter of 2026, suggesting further growth potential after recent record highs.
Editor’s Note: This prediction is significant as it indicates a bullish outlook on gold, which could impact investors and the commodities market. Understanding these trends can help investors make informed decisions.
US orders Delta and Aeromexico to dissolve partnership that allowed them to price and schedule their flights jointly and share revenue
NegativeFinancial Markets
The U.S. government has ordered Delta and Aeromexico to end their partnership, which allowed them to coordinate flight pricing and schedules. This decision follows claims from U.S. Transportation Secretary Sean Duffy that Mexico is treating U.S. airlines unfairly.
Editor’s Note: This matters because the dissolution of this partnership could impact flight options and prices for travelers. It highlights ongoing tensions between U.S. and Mexican airlines, potentially affecting competition and consumer choice in the aviation market.
Hitting an Inflection Point in Inferencing: Qiu
PositiveFinancial Markets
Lei Qiu, CIO at AllianceBernstein, discusses the expanding adoption of AI and the opportunities it presents, emphasizing the need for caution. She shares insights on Bloomberg Tech.
Editor’s Note: This discussion is significant as it highlights the growing role of AI in various sectors and the balance between embracing innovation and exercising caution. Understanding these dynamics can help businesses navigate the evolving landscape.
FDA warns Hims & Hers and other weight loss drugmakers to remove ‘false and misleading’ advertising
NegativeFinancial Markets
The FDA has issued over 100 letters to Hims & Hers and other weight loss drugmakers, warning them to stop using false and misleading advertising. This action highlights concerns about the integrity of marketing practices in the weight loss industry.
Editor’s Note: This matters because misleading advertising can lead consumers to make uninformed health decisions. The FDA's intervention aims to protect public health and ensure that companies provide accurate information about their products.
ServiceNow to Open AI Hub in Florida
PositiveFinancial Markets
ServiceNow is set to open an AI hub in West Palm Beach, Florida, creating 850 new jobs. This initiative is part of a new tower project developed by Stephen Ross.
Editor’s Note: This expansion highlights ServiceNow's commitment to growing its AI capabilities and workforce, which is significant for the local economy and the tech industry in Florida.